Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic
<p>The coronavirus disease 2019 (COVID-19) is spreading rapidly. Hydroxychloroquine (HCQ), an old drug for treatment of malaria and autoimmune disease with acceptable safety, has shown promising but yet unproven effect against COVID-19 infection. HCQ is an approved agent by the Drug Controller...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications,
2020-05-07.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_2455-5363_000027 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Anirban Majumder |e author |
| 245 | 0 | 0 | |a Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic |
| 260 | |b Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications, |c 2020-05-07. | ||
| 520 | |a <p>The coronavirus disease 2019 (COVID-19) is spreading rapidly. Hydroxychloroquine (HCQ), an old drug for treatment of malaria and autoimmune disease with acceptable safety, has shown promising but yet unproven effect against COVID-19 infection. HCQ is an approved agent by the Drug Controller General of India (DCGI) for the therapy of Type 2 Diabetes. In view of the fact that people with diabetes face higher chance of experiencing serious complications from COVID-19, HCQ may have preferential position as an antidiabetic agent during this crisis period.</p> | ||
| 540 | |a Copyright © Anirban Majumder et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Short Communication |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/2455-5363.000027 |z Connect to this object online. |